Purpose: e multifunctional RNA-binding protein, CUGBP1, regulates splicing, stability and translation of mRNAs. Previous studies have shown that CUGBP1 is expressed at high levels in the liver, although its role in hepatocellular carcinoma is unknown. Our aim was to determine if CUGBP1 could regulate hepatocellular carcinoma growth.
Liver carcinoma is the third most common cause of cancerrelated death [1] . Hepatocellular carcinoma, the most common type of liver cancer, is mostly caused by viral infection [2] . Many therapeutic methods have been used to extend the lifespan of patient; however, only 30-40% of patients are deemed suitable for curative intervention. New therapeutic methods and drug targets are needed for the treatment of hepatocellular carcinoma.
RNA binding proteins are involved in the regulation of gene expression in all tissues including regulation of biological processes in the liver. CUG-binding protein 1 (CUGBP1), referred to as CUGBP, Elav-like family member 1 (CELF1), was rst identi ed as a protein that binds to the RNA CUG repeats that are expanded in myotonicdystrophy type 1 (DM1) [3] . It is an RNA-binding protein that regulates the stability and translational e ciency of target mRNAs. CUGBP1 has been shown to regulate many posttranscriptional processes including alternative splicing, translation [4] , deadenylation and mRNA degradation [5, 6] . CUGBP1 mediates selective mRNA decay by binding to GU-rich elements (GREs) containing the sequence UGUUUGUUUGU that are found in the 3'-untranslated region (UTR) of short-lived transcripts [7] .
CUGBP1 is highly expressed in the liver and regulates translation of proteins that are critical for maintenance of liver functions [3, 8, 9] . CUGBP1 could form complexes with eukaryotic translation initiation factor eIF2 and support translation of C/EBPβ and HDAC1 proteins, which are involved in liver growth, di erentiation and liver cancer [10] [11] [12] [13] . CUGBP1 can interact with the region of C/EBPβ mRNA and produce more C/EBPβ-LIP over the active isoform of C/ EBPβ-LAP [14] . C/EBPβ-LIP is upregulated in hepatocellular carcinoma and regulates cell survival [15] . HDAC1is also shown to be highly expressed in hepatocellular carcinoma and may be involved in carcinoma aggressiveness and cell dedi erentiation [16] .
Although CUGBP1 is involved in the regulation of cell proliferation during liver regeneration [17, 13] , the function of CUGBP1 in liver carcinoma is largely unknown. In the present study, CUGBP1 was found to be highly expressed in human hepatocellular carcinoma specimens in comparison with normal liver specimens. To investigate the functional role of CUGBP1 in hepatocellular carcinoma, lentivirus-mediated short hairpin RNA (shRNA) was employed to silence CUGBP1 expression in the human hepatic carcinoma cell line, HepG2. e e ect of knocking down CUGBP1 on the proliferation and cell cycle distribution of HepG2 cells was then examined.
Methods

Immunohistochemistry
Seventy hepatic carcinoma tissue samples were collected for immunostaining (54 male, 16 female; mean age 59.1±10.7 years; range 34-80 years; 62 hepatocellular carcinoma, six bile duct carcinoma, two other types). Twenty normal hepatic tissue samples, four hepatocirrhosis tissue samples and 16 other liver disease tissue samples were used as controls. All above specimens were provided by the Department of Hepatobiliary Surgery, Changzhou Hospital of Traditional Chinese Medicine.
e tissue samples were formalin-xed and para nembedded. A er the para n was removed from the specimens, samples were blocked and incubated with anti-CUGBP1 (Santa Cruz Biotechnology, Shanghai China, sc-20003, dilution 1:50) overnight at 4°C. Samples were then washed with PBS and incubated with biotinylated secondary antibody for 30 min at room temperature. A er incubated with streptavidin peroxidase conjugate for 10 min at room temperature, DAB staining was performed.
All samples were counterstained with hematoxylin. Slides were interpreted by two pathologists and immunohistochemical-positive stained CUGBP1 protein was determined according to published methods [18] . e details of grading criteria are as follows: the number and staining degree of immunolabeled cells was counted manually on bright-eld microscopic images in 1 of every 10 saggital sections (coded). 0: no staining/staining cell numbers less than 10%; 1: yellowish/ staining cell numbers between 10%-30%; 2: brownish yellow/ staining cell numbers between 30%-60%; 3: dark brown/ staining cell numbers between more than 60%. en staining results were determined according to the sum of two scores and classied into four grades: 0: (-), 1-2: weak positive (-~+), 3-4: positive (+) and 5-6: hadro-positive (++).
Cell culture
Human hepatic carcinoma cell lines Bel-7404, SK-Hep-1, HepG2, Hep3B, SMMC-7721 and human embryonic kidney cell line 293T were maintained in DMEM medium (Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS), L-glutamine, penicillin and streptomycin at 37°C in a humidi ed 5% CO2 atmosphere. Bel-7402 cell line was cultured in 1640 medium (Hyclone) supplemented with 10% FBS under the same conditions. All cell lines are obtained from the Chinese Academy of Sciences. Construction of CUBGP1 shRNA plasmid CUGBP1 cDNA sequence was obtained from GenBank (NM_006560). A 63 bpshRNA was designed according to the CUBGP1 sequence (5'-CTAGCCGGGATTGAAGAATGC CGGATATTCAAGAGATATCCGGCATTCTTCAATCT TTTTAAT-3'). ShRNA (5'-CTAGCCCGGTTCTCCGAA CGTGTCACGTATCTCGAGATACGTGACACGTTCG GAGAATTTTTTTAAT-3') was used as control for unspeci c siRNA e ect in target cells. Both shRNA were cloned into lentiviralpFH-L plasmid (Shanghai Hollybio, Shanghai, China) using Nhe I/Pac I sites.
Lentivirus packaging and infection
For lentivirus packaging, 293T cells were transfected with pFH-L-CUGBP1 shRNA or control shRNA and two helper plasmids (pVSVG-I and pCMVΔR8.92, Shanghai Hollybio). irty-six hours a er transfection, the media containing the packaged lentivirus was collected and passed through 0.45 µm lters. HepG2 cells were subcultured at 5×10 4 cells per well in six-well tissue culture plates. A er 48 h of culture, HepG2 cells were added with prepared lentiviral particles at an MOI of 50.
Real-time qPCR analysis
Five days a er infection, HepG2 cells were collected for total RNA extraction. cDNA was obtained with oligodT using reverse transcriptase M-MLV (Promega, Madison USA) and subjected to real-time qPCR analysis using SYBR (Bio-Rad catalog number 170-8882). Primers were designed for CUGBP1 (Forward: 5'-ACCTGTTCATCTACCACCTG-3'; Reverse: 5'-GGCTTGCTGTCATTCTTCG-3'). Actin was used as control housekeeping gene (Forward: 5'-GTGGACATCCGC AAAGAC-3'; Reverse: 5'-AAAGGGTGTAACGCAACTA-3'). PCR system was 10 μl 2xSYBR premix ex-taq, 0.8 μL primers (2.5 μM), 5 μL cDNA and 4.2 μL ddH2O. e thermal pro le consisted of 1 cycle at 95°C for 1 min followed by 40 cycles at 95°C for 5 s and at 60°C for 20 s. e expression of CUBGP1 was checked by normalization of the cycle threshold (Ct) to that of the control housekeeping gene (actin) using the formula 2 -ΔΔCt . All real-time qPCR was done with BioRadConnet Real-Time PCR platform.
Western blot analysis
Five days a er infection, HepG2 cells were collected. Whole cell lysates were obtained using 2xSDS sample bu er (100 mM Tris-HCl (pH 6.8), 10 mM EDTA, 4% SDS, 10% glycine). A er running on the SDS-PAGE, proteins were separated and transferred to a membrane for immune-blotting. Primary antibodies are as following: anti-CUGBP1 (Santa Cruz, sc-20003, dilution 1:1000), anti-GAPDH (Santa Cruz Biotechnology, sc-32233, dilution 1:3000). e secondary antibodies are goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, sc-2005, dilution 1:5000).
MTT assay
HepG2 cells were subcultured at 2×10 3 cells per well in tissue culture plates. Five days a er lentivirus infection, cells were collected for MTT assay according to manufacturer's directions. Brie y, MTT solution was added to wells and incubated at 37°C for 4 h. e converted dye solubilized in acidic isopropanol (10% SDS, 5% isopropanol and 0.01 M HCl) was used and incubated at 37°C for 10 min. Cell density was monitored by optical density at 595 nm in an absorbance plate reader.
Cell cycle analysis
HepG2 cells were subcultured at 5×10 4 cells per well in 6 cm tissue culture plates. Five days a er lentivirus infection, HepG2 cells were subjected to ow cytometry analysis. Brie y, cells were harvested by trypsinization, washed with PBS, and xed with 70% cold ethanol. Cell cycle were evaluated by determining the DNA content a er propidium iodide (PI) staining using a Cell Cycle and Apoptosis Analysis Kit (C1052, Beyotime Institute of Biotechnology, Jiangsu, China), according to the manufacturer's protocol and analyzed by Cell Lab uanta Beckman Coulter.
Statistical analysis
e results of immunostaining were evaluated by χ 2 test and the other data were evaluated by Student's t test and expressed as means ± SD. Statistical analyses were performed using GraphPad Prism 5 and P<0.05 was considered as statistically signicant.
Results
CUGBP1 is highly expressed in hepatic carcinoma tissues
To examine the clinical signi cance of CUGBP1 in hepatocellular carcinoma, immunohistochemistry was performed on 70 hepatic carcinoma tissues along with 20 normal tissues, four hepatocirrhosis and 16 other liver disease tissues using the CUGBP1 antibody. CUGBP1 cytoplasmic staining was identi ed in 85.7% of cancer tissues (60/70), 50% of normal tissues (10/20), 100% of hepatocirrhosis (4/4), and 87.5% of other liver disease tissues (14/16) ( Table 1) . ere was a signi cant di erence among the four groups (**, P<0.01). Representative immunohistochemical staining for CUGBP1 in normal, cirrhosis and tumor tissues can be found in Figure 1 . It is clear that CUGBP1 was more highly expressed in cirrhosis and tumor tissues compared with normal tissues. Expression of CUGBP1 and its relationships with clinicopathological factors in 70 hepatic carcinoma were analyzed ( 
214).
Further studies on large cohorts of tissue specimens are necessary to determine the immunohistochemical stains of CUGBP1 as a possible diagnostic indicator.
CUGBP1 expression is downregulated by lentivirus-mediated shRNA
To con rm CUGBP1 expression in hepatic carcinoma, six human hepatic carcinoma cell lines were collected (SK-Hep-1, Bel-7402, Bel-7404, HepG2, Hep3B and SMMC-7721). Realtime qPCR analysis showed that the CUGBP1 gene was expressed in all hepatic carcinoma cell lines (Figure 2A ). To examine the function of CUGBP1 in hepatic carcinoma, lentivirus-mediated CUGBP1 shRNA or control shRNA were designed. As shown in Figure 2B , GFP signal was observed in 90% HepG2 cells 5 days a er lentivirus infection at MOI 50. Real-time qPCR analysis showed that the transcription level of CUGBP1 is 57.6% (*** P<0.001) less in HepG2 cells transfected with Lv-shCUGBP1 compared with control cells or cells transfected with Lv-shCon ( Figure 2C ). Western blot analysis further con rmed that the expression of CUGBP1 was decreased signi cantly 5 days a er infection with LvshCUGBP1 ( Figure 2D ). ese results indicated that lentivirus could e ciently deliver the shRNA into HepG2 cells and signi cantly knockdown the endogenous CUGBP1 expression in mRNA and protein levels.
Suppression of CUGBP1 inhibits HepG2 cell proliferation
Oncogenes are usually over-activated to promote proliferation and survival of tumor cells. In this study, the proliferation of 
Suppression of CUGBP1 a ects cell cycle and survival of HepG2 cells
Cell proliferation is usually regulated by the cell cycle, which is divided into a series of phases. To examine whether the cell cycle is a ected by the knockdown of CUGBP1, ow cytometry experiment was performed on HepG2 cells 5 days a er infection. Representative ow cytometry pro les were shown in Figure 4A . In control HepG2 cells, the ratios of cell in G0/G1, S and G2/M phase were 65.02%±2.00%, 12.87%±0.86% and 21.90%±1.44%, respectively. For Lv-shCon infected HepG2 cells, there were no signi cant di erences compared with control cells in di erent phases (G0/G1, 63.67%±2.67%; S, 12.50%±1.06%; G2/M, 23.80%±3.12%). Compared with those two groups, Lv-shCUBGP1 transfected HepG2 cells showed signi cantly increased cell population in G0/G1 phase (80.07%±1.86%, ** P<0.01), and decreased cell numbers in both S (9.26%±0.56%, * P<0.05) and G2/M phase (10.69%±1.48%, ** P<0.01). ese results suggested that HepG2 cells with CUGBP1 knockdown were arrested at G0/ G1 phase.
Further analysis of ow cytometry data showed a signicant increase in the sub-G1 cell population in HepG2 cells transfected with Lv-shCUGBP1 (10.29%±0.28%) compared with control cells (1.78%±1.13%) and cells transfected with Lv-shCon (2.09%±0.88%). is result indicated more apoptosis cells a er suppression of CUGBP1 (** P<0.01).
To further con rm that down-regulation of CUGBP1 could a ect the cell cycle in HepG2 cells, Western blot analysis was performed using cyclin B1 and cyclin D1 antibodies. As shown in Figure 4D , cyclin B1 was signi cantly downregulated, while cyclin D1 was signi cantly up-regulated in LvshCUGBP1 transfected cells.
Discussion
Liver carcinoma is the third leading cause of cancer-related death and responsible for about six million death annually [1, 19, 20] . Although many therapeutic methods have been used to extend the lifespan of patient, only 30-40% of patients are deemed suitable for curative intention [21] . New therapeutic methods and drug targets are urgently needed for the treatment of hepatocellular carcinoma. Highly speci c and apparent non-toxic, RNAi has been widely used to knockdown the expression of target genes [22] and may prove useful for the treatment of hepatocellular carcinomas.
e CUGBP1 and its target transcripts de ne a posttranscriptional regulatory network that functions to control cell growth regulation, cell motility, and apoptosis [6] . Recent studies have indicated that CUGBP1 may also play a signicant role in tumorgenesis and apoptosis [23, 24] . Depletion of CUGBP1 resulted in decreased cell viability, growth retardation, infertility and apoptosis in mice [9] . Knockdown of CUGBP1 in HeLa cells induced caspase-3 activation. Conversely, overexpression of CUGBP1 in HeLa cells prevented apoptosis under stress conditions by inducing expression of p21 [25] . In this study, CUGBP1 was found to be highly expressed in hepatocellular carcinoma specimens. Lentivirusmediated RNAiwas used to knockdown endogenous CUGBP1, and CUGBP1 silencing was found to signi cantly reduce the proliferation ability of hepatocellular carcinoma cells, suggesting that CUGBP1-inhibited hepatocellular carcinoma cell proliferation might occur though regulating the expression of C/EBPβ-LIP and HDAC1.
Previous studies found that CUGBP1 can regulate the level of cyclin-dependent kinase 4 (cdk4), which forms a complex with cyclin D1 and regulates cell cycle G1/S transition [26, 27] . As a positive regulator of cdk4, cyclin D1 has been implicated in the control of the G1 phase of the cell cycle. Cyclin B1 is the key initiator of mitosis [28, 29] . Cell cycle analysis showed that CUGBP1 knockdown restricted G1 to S phase progression. Further investigation demonstrated that CUGBP1 depletion resulted in upregulation of cyclin D1 and downregulation of cyclin B1. It is possible that one mechanism of CUGBP1 knockdown-inducing cell cycle arrest may be via the cyclin D1/cyclin B1 signaling pathway. Apoptosis-inducing agents are being investigated as tools for the management of cancer treatment. To detect apoptosis, sub-G1 phase cells were measured. Such cells are usually considered to be the result of apoptotic DNA fragmentation: during apoptosis, the DNA is degraded by cellular endonucleases. In the present study, accumulation of sub-G1 class in HepG2 cells was observed to vary signi cantly from control cells, which indicates cell apoptosis. Our further studies will be focused on the precise molecular mechanism of CUGBP1 in modulating cancer cell growth and apoptosis.
In conclusion, our results indicated that depletion of CUGBP1 by RNAi signi cantly inhibited hepatocellular carcinoma cell growth along with G0/G1 phase cell cycle arrest. Our studies suggest CUGBP1 may serve as a potential target for the treatment of hepatocellular carcinoma.
